Drug Trial Radar · NCT05542576
Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy
Last checked: Nov 19, 2026Latest source record: Aug 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
13
Actual
Start
Aug 24, 2022
Primary completion
Mar 15, 2023
Study completion Mar 15, 2023
Sponsor
- Lead sponsor
- Amydis Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this research study is to assess safety and tolerability of a single intravenous (given through a vein) dose of the investigational retinal tracer AMDX-2011P in patients with neurodegenerative diseases (Parkinson's disease and ALS).
Conditions
- Parkinson Disease
- Amyotrophic Lateral Sclerosis
Interventions
AMDX2011PDrug
AMDX2011P single bolus injection intravenous for diagnostic review
Primary outcomes
What the sponsor says the trial is designed to measure.
- AMDX-2011P Adverse Events ProfileTime frame: 1 week
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Eye Research Foundation
Newport Beach, California
Brittany NIcholl
Pasadena, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.